JP6512614B1 - Oral care agent - Google Patents
Oral care agent Download PDFInfo
- Publication number
- JP6512614B1 JP6512614B1 JP2017198897A JP2017198897A JP6512614B1 JP 6512614 B1 JP6512614 B1 JP 6512614B1 JP 2017198897 A JP2017198897 A JP 2017198897A JP 2017198897 A JP2017198897 A JP 2017198897A JP 6512614 B1 JP6512614 B1 JP 6512614B1
- Authority
- JP
- Japan
- Prior art keywords
- lps
- oral care
- care agent
- periodontal disease
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008375 oral care agent Substances 0.000 title claims abstract description 21
- 208000028169 periodontal disease Diseases 0.000 claims abstract description 19
- 208000003265 stomatitis Diseases 0.000 claims abstract description 12
- 239000002158 endotoxin Substances 0.000 claims description 41
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 41
- 241000520272 Pantoea Species 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 2
- 210000004195 gingiva Anatomy 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 abstract description 15
- 241000894006 Bacteria Species 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 238000000605 extraction Methods 0.000 abstract description 4
- 230000035876 healing Effects 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- 229940041672 oral gel Drugs 0.000 description 21
- 230000006866 deterioration Effects 0.000 description 12
- 210000000214 mouth Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000008961 swelling Effects 0.000 description 5
- 229940034610 toothpaste Drugs 0.000 description 4
- 239000000606 toothpaste Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000605862 Porphyromonas gingivalis Species 0.000 description 3
- 239000007910 chewable tablet Substances 0.000 description 3
- 210000004262 dental pulp cavity Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000013095 identification testing Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229940063199 kenalog Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 241000178435 Eliokarmos dubius Species 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 102000005482 Lipopolysaccharide Receptors Human genes 0.000 description 1
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 1
- 241000588912 Pantoea agglomerans Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
Abstract
【課題】口腔ケアのターゲットとなる歯周病菌あるいは歯周病菌の影響を効果的に抑制する方法を提供する。【解決手段】口腔ケア剤にＬＰＳを配合することで歯周病を改善できる。ＬＰＳは、自然治癒力を高める効果もあることから、ＬＰＳ配合の口腔ケア剤は、歯周病の改善のほか、抜歯後の歯肉の形成や口内炎等の予防も期待できる。【選択図】図１The present invention provides a method for effectively suppressing the influence of periodontitis bacteria or periodontitis bacteria targeted for oral care. SOLUTION: Periodontal disease can be improved by blending LPS into an oral care agent. Since LPS also has an effect of enhancing the natural healing power, oral care agents with LPS can be expected to prevent gum formation and stomatitis after tooth extraction, as well as improving periodontal disease. [Selected figure] Figure 1
Description
本発明は、口腔内の健康を保つための、リポポリサッカライド（ＬＰＳ）配合の口腔ケア剤に関する。 The present invention relates to a lipopolysaccharide (LPS) -containing oral care agent for maintaining oral health.
口腔ケアの基本は、口腔内を掃除して清潔にすることにある。口腔内を清潔にすることは、細菌のエサになる食物かすを取り除き、細菌の増殖を防止する。このことは歯周病や虫歯の予防のみならず、体内への細菌の感染を予防する。また歯周病や虫歯がなく健全な歯がそろっていれば、どんな食物も食べることができ、言葉が明瞭に発音でき、また口元にコンプレックスを持たずに笑うことができるので、生活の質を高めることにもつながる。これらのことから近年、特に高齢者に対し口腔ケアが重要視されるようになっている（非特許文献１）。 The basis of oral care is to clean and clean the oral cavity. Cleaning the oral cavity removes food debris that may be a food source of bacteria and prevents bacterial growth. This not only prevents periodontal disease and dental caries, but also prevents bacterial infection in the body. Also, if there is no periodontal disease or tooth decay and healthy teeth are in place, any food can be eaten, words can be pronounced clearly, and because you can laugh without having a complex in your mouth, you can improve the quality of life. It also leads to raising. From these things, in recent years, oral care has been regarded as particularly important for elderly people (Non-Patent Document 1).
口腔内の健康に最も悪影響を与える細菌が歯周病菌（ポルフィロモナス・ジンジバリス菌）である。歯周病菌は偏性嫌気性のグラム陰性細菌で、種々のプロテアーゼや毒性物質を放出して歯周組織を破壊する。莢膜や線毛を有しており、白血球の貪食作用や殺菌作用に抵抗性がある。糖質を代謝できず、主としてアミノ酸やたんぱく質を栄養素とするため、代謝物が悪臭の原因となる。口腔内疾患だけでなくリューマチの発症とも相関があるとされている（非特許文献２）。従って、歯周病菌を抑制することは、口腔ケアにおける必須事項となる。 The bacteria that most adversely affect the health in the oral cavity are periodontitis (porphyromonas gingivalis). Periodontitis is an obligate, anaerobic, gram-negative bacterium that releases various proteases and toxic substances to destroy periodontal tissue. It has a capsule and pilus and is resistant to the phagocytosis and bactericidal action of white blood cells. Metabolites cause malodor because they can not metabolize carbohydrates and mainly contain amino acids and proteins as nutrients. It is believed that there is a correlation not only with intraoral diseases but also with rheumatism (Non-patent Document 2). Therefore, suppressing periodontal disease is an essential item in oral care.
歯周病菌は偏性嫌気性菌であることから、口腔内粘膜表面や歯の表面で生育しているわけではなく、通常の歯磨きで除去することが難しい。一方歯周病菌がグラム陰性細菌であることから、グラム陰性細菌の細胞壁成分であるリポポリサッカライド（ＬＰＳ）が炎症を誘導することが歯周病の元凶であり、ＬＰＳを除去すれば歯周病を抑制できると考え、ＬＰＳを除去することを標ぼうする歯磨き粉が販売されている（非特許文献３）。ところが、この菌のＬＰＳは構造が特殊であってＬＰＳレセプターであるＴＬＲ４には結合せず、炎症性サイトカインの誘導も顕著に低いのである（非特許文献４）。この点から、歯周病菌の炎症誘導作用は歯周病菌のＬＰＳに負うものではなく、ＬＰＳを除去することで歯周病を予防することはできないことがわかる。このように、現状で、歯周病菌あるいは歯周病菌の影響を効果的に抑制する方法は未だ開発されていない。 Since periodontitis is an obligate anaerobe, it does not grow on the surface of the oral cavity mucous membrane or on the surface of teeth, and it is difficult to remove it with ordinary tooth brushing. On the other hand, since periodontal disease bacteria are gram-negative bacteria, induction of inflammation is caused by lipopolysaccharide (LPS), which is a cell wall component of gram-negative bacteria. Toothpaste is marketed, which purports to remove LPS by thinking that it can suppress However, LPS of this bacterium is special in structure and does not bind to TLR4 which is an LPS receptor, and induction of inflammatory cytokines is also significantly low (Non-patent Document 4). From this point, it is understood that the inflammation-inducing action of periodontitis is not due to LPS of periodontitis, and it is not possible to prevent periodontal disease by removing LPS. Thus, at present, methods for effectively suppressing the influence of periodontitis bacteria or periodontitis bacteria have not been developed yet.
口腔ケアのターゲットとなる歯周病菌あるいは歯周病菌の影響を効果的に抑制する方法を提供する。 Provided is a method for effectively suppressing the influence of periodontitis or periodontal disease which is a target of oral care.
歯周病菌はグラム陰性細菌であるが、そのＬＰＳはＴＬＲ２に結合するため、本来のＬＰＳとしての自然免疫活性化作用を持っていない（非特許文献４）。このことが、歯周病菌が排除されない理由と考えられる。従って、自然免疫を活性化する作用のある物質を歯磨きあるいは口腔ジェル、チュアブルタブレット等の口腔ケア剤に配合すれば、宿主の持っている免疫力が高まり、歯周病菌が排除できると考えられる。 Periodontitis is a gram-negative bacterium, but since its LPS binds to TLR2, it does not have an innate immune activating action as natural LPS (Non-patent Document 4). This is considered to be the reason why periodontitis is not eliminated. Therefore, it is considered that if a substance having an action to activate innate immunity is blended in a toothpaste or an oral care agent such as an oral gel, a chewable tablet, etc., the immunity possessed by the host can be enhanced and periodontitis bacteria can be eliminated.
ところで、自然免疫を経口で安全に活性化する物質としてパントエア・アグロメランスのＬＰＳが知られている（非特許文献５）。一般にＬＰＳは炎症を誘導し、歯周病を悪化させる原因とされており、ＬＰＳを除去することを謳う歯磨きが販売されている（非特許文献３）。しかし発明者らは、パントエア・アグロメランスのＬＰＳを含む口腔ケア剤で口腔内を洗浄することで、歯周病菌の改善がみられることを発見した。 By the way, LPS of Pantoea Agromelans is known as a substance which activates innate immunity safely and orally (nonpatent literature 5). In general, LPS is considered to be a cause of inflammation and exacerbation of periodontal disease, and toothpaste is marketed that toothpaste removes LPS (Non-patent Document 3). However, the inventors discovered that cleaning of the oral cavity with an oral care agent containing LPS from Pantoea agglomerans improved periodontitis bacteria.
このことから、口腔ケア剤にＬＰＳを配合することで歯周病を改善できる。ＬＰＳは、自然治癒力を高める効果もあることから、ＬＰＳ配合の口腔ケア剤は、歯周病の改善のほか、抜歯後の歯肉の形成や口内炎等の予防も期待できる。 From this, periodontal disease can be improved by blending LPS in the oral care agent. Since LPS also has an effect of enhancing the natural healing power, oral care agents with LPS can be expected to prevent gum formation and stomatitis after tooth extraction, as well as improving periodontal disease.
本発明の口腔ケア剤は、パントエア・アグロメランスのリポポリサッカライドを有効成分として含むことを特徴とする。
また、前記口腔ケア剤が、歯周病に対するものであることを特徴とする。
また、前記口腔ケア剤が、術後の歯肉に対するものであることを特徴とする。
また、前記口腔ケア剤が、口内炎に対するものであることを特徴とする。
The oral care agent of the present invention is characterized in that it comprises Pantoea Agromelans lipopolysaccharide as an active ingredient.
In addition, the oral care agent is characterized in that it is for periodontal disease.
Further, the invention is characterized in that the oral care agent is for post-operative gingiva.
In addition, the oral care agent is characterized in that it is for stomatitis.
本発明の口腔ケア剤は、一般的な口腔ケア剤として、特に、歯周病及び口内炎の治療、並びに術後の歯肉ケアに有効である。 The oral care agent of the present invention is effective as a general oral care agent, in particular, in the treatment of periodontal disease and stomatitis, and post-operative gingival care.
［ＬＰＳ配合口腔用ジェルの製造］
ＬＰＳ（パントエア・アグロメランス／コムギ粉発酵エキス）配合口腔用ジェルの配合および製造方法を以下に示す。
水にＡ成分を添加し８０℃にて加熱溶解する。これにＤを加熱溶解し透明溶液とする。
[Production of LPS-containing oral gel]
The formulation and production method of the oral gel for LPS (pantoea Agromelans / wheat flour fermented extract) combination are shown below.
Add component A to water and heat to dissolve at 80 ° C. Heat and dissolve D in this to make a clear solution.
これを６０℃まで冷却後、Ｂを添加し６０℃にて高速攪拌して透明なジェルを調整する。この透明ジェルを攪拌しながら室温まで冷却後、Ｃを加え攪拌して分散後、さらにＥおよびＦを添加し、充分に攪拌することで口腔用ジェルを得る。 After cooling this to 60 ° C., add B and stir at 60 ° C. at high speed to prepare a clear gel. After cooling this transparent gel to room temperature while stirring, C is added and stirred to be dispersed, and E and F are further added, and oral gel is obtained by sufficiently stirring.
［ＬＰＳ配合チュアブルタブレットの製造］
ＬＰＳ（パントエア・アグロメランス／コムギ粉発酵エキス）配合チュアブルタブレット（500mg/粒）の配合成分を以下に示す。
[Production of LPS-blended chewable tablets]
The components of the chewable tablet (500 mg / grain) blended with LPS (pantoea agromelans / wheat flour extract) are shown below.
※２ EC-12
※ 2 EC-12
［ＬＰＳ配合口腔用ジェルによる歯周病の改善］
歯科クリニックに通う歯周病患者１８名に、実施例１で製造したＬＰＳ配合口腔用ジェルを１週間使用してもらい、歯周病の腫れについて５段階（悪化、やや悪化、変化なし、やや改善、改善）での本人評価試験を行った。使用方法は、ＬＰＳ配合口腔用ジェルを、１日に３回から４回、患部に指先でつけるか、または歯ブラシにつけて患部をブラッシングすることとし、塗布後の洗浄はしないこととした。結果は図１のとおりであった。悪化、やや悪化はゼロで、１８人中１５人が改善と回答した（図１左）。
[Amelioration of periodontal disease by LPS-containing oral gel]
Eighteen patients with periodontal disease who attend a dental clinic use the LPS-containing oral gel prepared in Example 1 for one week, and have five stages of swelling of periodontal disease (deterioration, slight deterioration, no change, slight improvement) Carried out a personal identification test under The method of use was such that the LPS-containing oral gel was attached to the affected area with a fingertip three to four times a day with a fingertip or put on a toothbrush to brush the affected area, and was not washed after application. The results are as shown in FIG. Deterioration and slight deterioration were zero, and 15 out of 18 persons answered that they improved (Figure 1 left).
別途、ＬＰＳ非配合口腔用ジェルを、同様の方法で、歯周病患者１２人に試してもらった結果、１名が悪化、６名が変化なし、５名がやや改善と回答した（図１右）。 Separately, as a result of having 12 patients with periodontitis try a gel without LPS mixed in the same way, one person deteriorated, 6 persons showed no change, and 5 persons said that they improved slightly (Fig. 1 right).
５段階（悪化、やや悪化、変化なし、やや改善、改善）の評価を、改善なし（悪化、やや悪化、変化なし）と改善あり（やや改善、改善）の二通りに分け、オッズ比をとると、ＬＰＳ配合口腔用ジェル群のＬＰＳ非配合口腔用ジェル群に対する改善のオッズ比は７．００（９５％信頼区間：１．２９〜３７．９）であった。これらの結果から、ＬＰＳ配合口腔用ジェルに、歯周病改善効果があることが示された。 The odds ratio is divided into five grades (deterioration, slight deterioration, no change, slight improvement, improvement) with no improvement (deterioration, slight deterioration, no change) and improvement (slight improvement, improvement). And, the odds ratio of the improvement to the LPS non-combination oral gel group for the LPS combination oral gel group was 7.00 (95% confidence interval: 1.29 to 37.9). From these results, it was shown that the LPS-containing oral gel has a periodontal disease ameliorating effect.
［ＬＰＳ配合口腔用ジェルによる抜歯後、根管治療後の歯肉の治癒］
歯科クリニックにて、抜歯を行った患者１名、根管治療後の患者１名に、実施例１で製造したＬＰＳ配合口腔用ジェルを１週間使用してもらい、処置後の痛み、腫れ、出血について本人評価試験を行った。使用方法は、ＬＰＳ配合口腔用ジェルを、１日に３回から４回、患部に指先でつけることとし、塗布後の洗浄はしないこととした。その結果、痛み、改善、腫れとも改善したとの評価であった。図２（写真１）に示されるように、根管治療患者において、試験前には、歯茎に腫れが見られるところ、試験後には腫れがひいていることがわかる。
[Gingival healing after root canal treatment after tooth extraction with LPS-containing oral gel]
At the dental clinic, one patient who had an tooth extraction and one patient after root canal treatment used the LPS-containing oral gel prepared in Example 1 for one week, and after treatment pain, swelling, bleeding Conducted a personal evaluation test. The method of use was that the LPS-containing oral gel was attached to the affected area with a fingertip three to four times a day, and was not washed after application. As a result, it was evaluated that pain, improvement, and swelling were all improved. As shown in FIG. 2 (photograph 1), in the endodontic patients, when swelling is observed in the gums before the test, it can be seen that the swelling is exacerbated after the test.
［ＬＰＳ配合口腔用ジェルによる口内炎の改善］
歯科クリニックに通う患者のうち、口内炎ができやすい体質の１０名に、実施例１で製造したＬＰＳ配合口腔用ジェルを１週間使用してもらい、口内炎について５段階（悪化、やや悪化、変化なし、やや改善、改善）での本人評価試験を行った。使用方法は、ＬＰＳ配合口腔用ジェルを、１日に３回から４回、患部に指先でつけることとし、塗布後の洗浄はしないこととした。結果は図３、図４のとおりであった。ステロイドを使っているという１名に悪化が見られたものの。１０名中８名が改善と回答した。また、図３（写真２）に見られるように、義歯との接触による褥瘡性潰瘍では、試験前に見られた歯肉表面のぼつぼつが試験後には消えてなめらかになった。口内炎の場合、通常は医薬品であるケナログ軟膏が処方されるが、ケナログ軟膏では治癒に１週間程度かかるとされている。一方、ＬＰＳ配合口腔用ジェルでの改善は速く、改善者８名のうち半数が、翌日には治癒したと回答した。１０名の口内炎患者の試験結果を集計すると、やや悪化１名、変化なし１名、やや改善２名、改善が６名であった（図４左）。
別途、プラセボ（ＬＰＳ非配合口腔用ジェル）を、同様の方法で、口内炎患者２人に試してもらった結果、２名とも変化なしと回答した（図４右）。
[Amelioration of stomatitis with LPS-containing oral gel]
Among patients who go to a dental clinic, 10 people with a constitution that can easily cause canker sores use the LPS-containing oral gel prepared in Example 1 for one week, and there are five stages of canker sores (deterioration, slight deterioration, no change, Conducted a personal identification test with a little improvement (improvement). The method of use was that the LPS-containing oral gel was attached to the affected area with a fingertip three to four times a day, and was not washed after application. The results are as shown in FIG. 3 and FIG. Although one person who used a steroid had a deterioration. Eight out of ten answered that they improved. In addition, as seen in FIG. 3 (Photo 2), in the case of decubitus ulcer caused by contact with the denture, the surface roughness of the gum surface observed before the test disappeared and became smooth after the test. In the case of stomatitis, kenalog ointment, which is a medicine, is usually prescribed, but with kenalog ointment, it takes about one week to cure. On the other hand, improvement with LPS-containing oral gel was quick, and half of the eight improvement workers answered that they were healed the next day. When the test results of 10 patients with stomatitis were totaled, 1 was slightly worse, 1 was unchanged, 2 was slightly improved, and 6 was improved (FIG. 4 left).
Separately, as a result of having a placebo (LPS non-formulation oral gel) tested by two patients with stomatitis in the same manner, both of them answered that there was no change (FIG. 4 right).
５段階（悪化、やや悪化、変化なし、やや改善、改善）の評価に対し、それぞれ−２、−１、０、１、２と配点し、それぞれ人数と掛け合わせた数字を総合し、さらに試験人数で割った値は、ＬＰＳ配合口腔用ジェルは１．３、ＬＰＳ非配合口腔用ジェルは０となる。プラセボ群の人数が少ないため統計処理はできないものの、これらの結果から、ＬＰＳ配合口腔用ジェルに、口内炎改善の傾向があることが示された。
For evaluation of 5 levels (deterioration, a little aggravation, no change, a little improvement, amelioration), the points are -2, -1, 0, 1 and 2, respectively, and the numbers are multiplied by the number of people respectively The value divided by the number of people is 1.3 for LPS-containing oral gel and 0 for non-LPS-containing oral gel. Although statistical treatment can not be performed due to the small number of people in the placebo group, these results indicate that the LPS-containing oral gel tends to improve stomatitis.
Claims (4)
An oral care agent characterized by comprising Pantoea Agromelans lipopolysaccharide as an active ingredient.
The oral care agent according to claim 1, wherein the oral care agent is for stomatitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017198897A JP6512614B1 (en) | 2017-10-12 | 2017-10-12 | Oral care agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017198897A JP6512614B1 (en) | 2017-10-12 | 2017-10-12 | Oral care agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP6512614B1 true JP6512614B1 (en) | 2019-05-15 |
| JP2019073456A JP2019073456A (en) | 2019-05-16 |
Family
ID=66530726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017198897A Active JP6512614B1 (en) | 2017-10-12 | 2017-10-12 | Oral care agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6512614B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021127311A (en) * | 2020-02-12 | 2021-09-02 | 自然免疫応用技研株式会社 | Oral care agent |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160058772A (en) * | 2013-10-03 | 2016-05-25 | 닛토덴코 가부시키가이샤 | Mucosal vaccine composition |
| US10688120B2 (en) * | 2015-05-01 | 2020-06-23 | Nitto Denko Corporation | Allergy vaccine composition |
-
2017
- 2017-10-12 JP JP2017198897A patent/JP6512614B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019073456A (en) | 2019-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Quirynen et al. | The intra‐oral translocation of periodontopathogens jeopardises the outcome of periodontal therapy: A review of the literature | |
| Meyer et al. | An early oral health care program starting during pregnancy: results of a prospective clinical long-term study | |
| Franco Neto et al. | Comparative analysis of the effect of two chlorhexidine mouthrinses on plaque accumulation and gingival bleeding | |
| Shah et al. | Efficacy of silver diamine fluoride as an antibacterial as well as antiplaque agent compared to fluoride varnish and acidulated phosphate fluoride gel: An: in vivo: study | |
| Zanela et al. | The influence of mouthrinses with antimicrobial solutions on the inhibition of dental plaque and on the levels of mutans streptococci in children | |
| Ripari et al. | The role of coconut oil in treating patients affected by plaque-induced gingivitis: A pilot study | |
| Nicolini et al. | Efficacy of ozonated water mouthwash on early plaque formation and gingival inflammation: a randomized controlled crossover clinical trial | |
| RU2550957C1 (en) | Method of treating chronic generalised periodontitis | |
| JP6512614B1 (en) | Oral care agent | |
| Rapp et al. | Dental caries in geriatric dentistry: an update for clinicians | |
| Epstein et al. | Enhancing the effect of oral hygiene with the use of a foam brush with chlorhexidine | |
| RU2158125C1 (en) | Composition for preventing and treating diseases of periodontium and oral cavity mucosa | |
| Singh et al. | Comparative evaluation between honey and chlorhexidine gluconate on the dental plaque levels and gingival health | |
| Eshwar et al. | Suppl-1, M8: Comparison of Dill Seed Oil Mouth Rinse and Chlorhexidine Mouth Rinse on Plaque Levels and Gingivitis-A Double Blind Randomized Clinical Trial | |
| Ismail et al. | The extend and reasons behind the use of herbal medicine as an alternative treatment in dentistry | |
| Kim et al. | The effect of mouthwash with Sambucus williamsii var. coreana extract on halitosis: a randomised, double-blind, placebo-controlled study | |
| Kreve et al. | Clinical evaluation of hygiene maintenance of full-arch implant-supported prostheses | |
| Moghaddas et al. | Effect of Ardox-X Active Oxygen-Containing Toothpaste on Periodontal Parameters in Dentate and Implant-Wearing Patients | |
| RU2605260C1 (en) | Method of integrated treatment of patients with inflammatory periodontal diseases | |
| Mosaico et al. | Resolution of an Atypical Gingival Swelling Unrelated to Plaque and Tartar Treated with Probiotics of the Lactobacillus reuteri Group: A Long-term Success | |
| RU2549445C1 (en) | Method of treating periodontitis and oral mucosal diseases associated with helicobacter infection, and method for using it | |
| Andini et al. | Toothpaste containing sodium bicarbonate, sodium fluoride, and potassium nitrate for dentine hypersensitivity with periodontal inflammation | |
| RU2661612C1 (en) | Method of non-specific donozological prophylaxis and treatment of dental caries in children of tender age | |
| Tambe et al. | Papillon lefevre syndrome‐A literature review and case report | |
| Valijonovna | Normal Microflora and Sanation of the Oral Cavity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20171204 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181102 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190403 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190403 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6512614 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |